Sökning: id:"swepub:oai:DiVA.org:uu-524569" >
Treatment-free remi...
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
-
- Flygt, Hjalmar (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden
-
- Söderlund, Stina (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden
-
- Richter, Johan (författare)
- Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden
-
visa fler...
-
- Saussele, Susanne (författare)
- Medical Clinic, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany
-
- Koskenvesa, Perttu (författare)
- Department of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
-
- Stenke, Leif (författare)
- Department of Hematology, Karolinska University Hospital and Department of Medicine, Karolinska Institutet, Stockholm, Sweden
-
- Mustjoki, Satu (författare)
- Department of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland; ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland
-
- Dimitrijevic, Andreja (författare)
- Department of Hematology, Odense University Hospital, Odense, Denmark
-
- Stentoft, Jesper (författare)
- Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
-
- Majeed, Waleed (författare)
- Department of Hemato-Oncology, Stavanger University Hospital, Stavanger, Norway
-
- Roy, Lydia (författare)
- French CML group Fi-LMC, Centre Léon Bérard, Lyon, Hôpital Universitaire Henri Mondor, AP-HP, Service d'hématologie Clinique & Faculté de Santé, Université Paris Est Créteil, Créteil, France
-
- Wolf, Dominik (författare)
- Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Tyrolean Cancer Research Institute (TKFI), Medical University Innsbruck, Innsbruck, Austria; Medical Clinic 3, Universitätsklinikum, Bonn, Germany
-
- Dreimane, Arta (författare)
- Department of Hematology, Linköping University Hospital, Linköping, Sweden
-
- Gjertsen, Bjørn Tore (författare)
- Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway
-
- Gedde-Dahl, Tobias (författare)
- Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
-
- Ahlstrand, Erik, 1974- (författare)
- Region Örebro län,Örebro universitet, Institutionen för medicinska vetenskaper,Department of Medicine
-
- Markevärn, Berit (författare)
- Department of Hematology, Umeå University Hospital, Umeå, Sweden
-
- Hjorth-Hansen, Henrik (författare)
- Department of Hematology, St. Olavs Hospital, Trondheim, Norway
-
- Janssen, Jeroen (författare)
- Department of Hematology, Radboud University medical center, Nijmegen, The Netherlands
-
- Olsson-Strömberg, Ulla (författare)
- Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2024
- 2024
- Engelska.
-
Ingår i: Leukemia. - : Springer. - 0887-6924 .- 1476-5551.
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov ID: NCT03573596) is a prospective study including patients with a failed first TFR attempt re-treated with any TKI for ≥ one year. Upon entering the study, patients received the TKI dasatinib for additional two years. Patients with sustained DMR for ≥1 year qualified for a second TKI stop. Ninety-four patients were included between Oct 2017-Dec 2021. At the time of data analysis, 62 patients had attempted a 2nd stop. After a median follow-up of 27 months from 2nd stop, TFR rates were 61, 56 and 46% at 6, 12 and 24 months respectively. No progression to advanced stage disease was seen and 87% had re-achieved MR4 within a median of 3 months from TKI re-initiation. In summary, we show that a 2nd TFR attempt after dasatinib treatment is safe, feasible and TFR rates seem in the range of those reported in trials of a first TKI stop.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Nyckelord
- Medicinsk vetenskap
- Medical Science
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Leukemia
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Flygt, Hjalmar
-
Söderlund, Stina
-
Richter, Johan
-
Saussele, Susann ...
-
Koskenvesa, Pert ...
-
Stenke, Leif
-
visa fler...
-
Mustjoki, Satu
-
Dimitrijevic, An ...
-
Stentoft, Jesper
-
Majeed, Waleed
-
Roy, Lydia
-
Wolf, Dominik
-
Dreimane, Arta
-
Gjertsen, Bjørn ...
-
Gedde-Dahl, Tobi ...
-
Ahlstrand, Erik, ...
-
Markevärn, Berit
-
Hjorth-Hansen, H ...
-
Janssen, Jeroen
-
Olsson-Strömberg ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Leukemia
- Av lärosätet
-
Uppsala universitet
-
Örebro universitet
-
Karolinska Institutet